What comes after CDK4/6 inhibitors? SERDs, combinations and the future of HR+ advanced breast cancer

Take-home:

The treatment options after a CDK4/6 inhibitor with endocrine therapy in HR-positive, HER2-negative advanced breast cancer, and the emerging role of SERD-based combinations.

The post-CDK4/6 inhibitor setting in HR-positive, HER2-negative advanced breast cancer is one of the most pressing unmet needs in oncology. CDK4/6 inhibitors with endocrine therapy are the established first-line standard, but disease progression on this backbone remains nearly universal, driven by varied resistance mechanisms: ESR1 mutations, PI3K/AKT/mTOR pathway alterations and RB1 loss. That diversity shows the limits of one-size-fits-all approaches.

Next-generation oral SERDs, such as elacestrant, camizestrant and imlunestrant, are reshaping the field. They degrade the estrogen receptor more completely than fulvestrant, are active in ESR1-mutant disease, and are being actively evaluated in combination strategies with CDK4/6 and targeted therapies. Together, they are helping shift the post-CDK4/6 setting toward a more dynamic, biomarker-informed treatment paradigm.

Type
Expert discussion
Published
Length
14 minutes
Support
Supported by an unrestricted educational grant from Roche. All content was independently developed and fully controlled by the faculty.
Topic
Breast

More from OncoAlert Horizons

OncoAlert’s educational series: two experts on one evolving question in practice, a focus at a time. The next discussion is first.